NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis $8.29 +5.00 (+151.98%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.16▼$9.4050-Day Range$2.91▼$8.2952-Week Range$2.81▼$30.06Volume48.51 million shsAverage Volume376,434 shsMarket Capitalization$4.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Windtree Therapeutics alerts: Email Address Windtree Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy10.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.38) to ($2.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.81 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Windtree Therapeutics.Read more about Windtree Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted10.66% of the float of Windtree Therapeutics has been sold short.Short Interest Ratio / Days to CoverWindtree Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Windtree Therapeutics has recently decreased by 17.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldWindtree Therapeutics does not currently pay a dividend.Dividend GrowthWindtree Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for WINT. Previous Next 3.0 News and Social Media Coverage News SentimentWindtree Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Windtree Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for WINT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Windtree Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Windtree Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of Windtree Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.33% of the stock of Windtree Therapeutics is held by institutions.Read more about Windtree Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Windtree Therapeutics are expected to grow in the coming year, from ($2.38) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Windtree Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Windtree Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWindtree Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Windtree Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Windtree Therapeutics Stock (NASDAQ:WINT)Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitorfor the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.Read More WINT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WINT Stock News HeadlinesJuly 26 at 8:01 AM | investorplace.comWhy Is Windtree Therapeutics (WINT) Stock Up 116% Today?July 25 at 11:30 PM | marketwatch.comWindtree Therapeutics Up 61% After Hours on Withdrawn Equity OfferingJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 8:36 AM | finance.yahoo.comWindtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial DataJuly 25 at 8:00 AM | globenewswire.comWindtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial DataJuly 24 at 12:53 AM | bizjournals.comCash-strapped Windtree Therapeutics closes $12.9M financing dealJuly 23 at 5:04 AM | stockhouse.comWindtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred StockMay 9, 2024 | msn.comWindtree Therapeutics Regains Nasdaq Compliance with Minimum Bid Price RequirementJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 7, 2024 | finance.yahoo.comWindtree Therapeutics Regains Compliance with NasdaqMay 4, 2024 | morningstar.comWindtree Therapeutics Inc WINTApril 22, 2024 | bizjournals.comWindtree Therapeutics is dangerously low on cashApril 21, 2024 | msn.comWindtree Therapeutics Announces Reverse Stock Split in Strategy to Boost Market ComplianceApril 18, 2024 | msn.comWhy Windtree Therapeutics (WINT) Stock Is Getting HammeredApril 18, 2024 | globenewswire.comWindtree Therapeutics Announces Reverse Stock SplitApril 17, 2024 | finance.yahoo.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 17, 2024 | globenewswire.comWindtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business UpdatesApril 9, 2024 | finanznachrichten.deWindtree Therapeutics: Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge FinancingSee More Headlines Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:WINT CUSIPN/A CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($36.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-216.16% Return on Assets-58.88% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book0.82Miscellaneous Outstanding Shares592,000Free Float589,000Market Cap$4.91 million OptionableNot Optionable Beta0.56 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Craig E. Fraser (Age 59)Chairman, President, CEO & Interim Principal Officer Comp: $567.2kMr. Eric L. Curtis M.B.A. (Age 56)Senior VP & COO Comp: $411.3kDr. Steven G. Simonson M.D. (Age 65)M.H.S, Senior VP & Chief Medical Officer Comp: $448kMs. Jamie McAndrew (Age 43)VP, Controller, Chief Accounting Officer & Corporate Secretary Mr. George Cox (Age 72)Vice President of Technical Operations Dr. Pratap ParuchuruExecutive Director of Clinical DevelopmentMs. Tracy RarickHead of Operations & Program ManagementMore ExecutivesKey CompetitorsOrganovoNASDAQ:ONVOChromocell TherapeuticsNYSE:CHROTC BiopharmNASDAQ:TCBPFresh Tracks TherapeuticsNASDAQ:FRTXTitan PharmaceuticalsNASDAQ:TTNPView All CompetitorsInsidersCraig FraserBought 138 shares on 9/26/2023Total: $2,235.60 ($16.20/share)View All Insider Transactions WINT Stock Analysis - Frequently Asked Questions How have WINT shares performed this year? Windtree Therapeutics' stock was trading at $12.9420 at the beginning of 2024. Since then, WINT shares have decreased by 35.9% and is now trading at $8.29. View the best growth stocks for 2024 here. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) issued its quarterly earnings results on Wednesday, May, 15th. The company reported ($9.25) earnings per share (EPS) for the quarter. When did Windtree Therapeutics' stock split? Shares of Windtree Therapeutics reverse split on Monday, April 22nd 2024. The 1-18 reverse split was announced on Monday, April 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WINT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.